ReviewiLIVER2026
Targeting tumor-associated macrophages in pancreatic cancer.
Review in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated macrophages (TAMs) constitute a major immune cell population within the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment and play pivotal roles in tumor progression, immune evasion, stromal remodeling, and therapeutic resistance. Classically activated M1 macrophages generally exert anti-tumor effects, while alternatively activated M2-like macrophages predominantly facilitate tumor growth and immunosuppression. In this review, we aim to systematically summarize the current understanding of TAM polarization, subtype-specific functions, and emerging macrophage-targeted therapeutic strategies in PDAC, with particular emphasis on translational advances and existing clinical challenges. A comprehensive literature review was conducted focusing on TAM biology, key signaling pathways involved in macrophage polarization, preclinical therapeutic approaches, and currently available clinical trial evidence in PDAC. Multiple signaling pathways, including colony-stimulating factor 1/colony stimulating factor 1 receptor, janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3), phosphatidylinositol 3-kinase -γ, cluster of differentiation 40, and toll-like receptor-associated pathways, have been implicated in TAM polarization in PDAC. Current therapeutic strategies mainly involve promoting M1 polarization, depleting M2-like macrophages, and reprogramming immunosuppressive TAMs toward anti-tumor phenotypes. Promising therapeutic agents include selicrelumab, ruxolitinib, colony stimulating factor 1 receptor inhibitors, spleen tyrosine kinase inhibitors, and Toll-like receptor agonists. In addition, neoadjuvant FOLFIRINOX chemotherapy may enhance M1-like macrophage infiltration through immunogenic cell death and TME remodeling. However, several strategies remain largely at the preclinical stage. Direct evidence supporting certain subtype-specific mechanisms, particularly those involving M2b macrophages in PDAC, remains limited. Overall, TAM-targeted therapy represents a promising immunotherapeutic strategy for PDAC. Future clinical translation will depend on improved target specificity, biomarker-guided patient stratification, and rational combination therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.